Plasmid DNA and viral vector-based vaccines for the treatment of cancer

Vaccine

Volumn 25, Issue SUPPL. 2, 2007, Pages

  Anderson, Richard J ^a   Schneider, Joerg ^a  

^a Oxxon Therapeutics Ltd   (United Kingdom)

Author keywords

Cancer vaccines; DNA vaccines; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CANARYPOX VIRUS VACCINE; CANCER VACCINE; CISPLATIN; DNA VACCINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN; MUCIN 1; NAVELBINE; OXALIPLATIN; PLASMID DNA; SUNITINIB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ADJUVANT THERAPY; CANARYPOX VIRUS; CANCER IMMUNIZATION; CANCER THERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG MECHANISM; HETEROLOGOUS EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; MODIFIED VACCINIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINIA VIRUS; VIRUS ATTENUATION;

ANIMALS; CANCER VACCINES; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; NEOPLASMS; PLASMIDS; VACCINES, DNA; VIRAL VACCINES;

EID: 34848903876     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.030     Document Type: Review

References (110)

1. Hoption Cann S.A., van Netten J.P., and van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79 (2003) 672-680
2. Maryanski J.L., Van Snick J., Cerottini J.C., and Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 12 (1982) 401-406
3. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
4. Powell D.J.J., Dudley M.E., Hogan K.A., Wunderlich J.R., and Rosenberg S.A. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177 (2006) 6527-6539
5. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
6. Kawakami Y., Nishimura M.I., Restifo N.P., Topalian S.L., O'Neil B.H., Shilyansky J., et al. T-cell recognition of human melanoma antigens. J Immunother 14 (1993) 88-93
7. Drake C.G., Jaffee E., and Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006) 51-81
8. Seliger B. Strategies of tumor immune evasion. BioDrugs 19 (2005) 347-354
9. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
10. Schalk J.A., Mooi F.R., Berbers G.A., van Aerts L.A., Ovelgonne H., and Kimman T.G. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2 (2006) 45-53
11. Conry R.M., Curiel D.T., Strong T.V., Moore S.E., Allen K.O., Barlow D.L., et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8 (2002) 2782-2787
12. Triozzi P.L., Aldrich W., Allen K.O., Carlisle R.R., LoBuglio A.F., and Conry R.M. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 28 (2005) 382-388
13. Rosenberg S.A., Zhai Y., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90 (1998) 1894-1900
14. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 (2006) 1650-1660
15. Tagawa S.T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98 (2003) 144-154
16. Fuller D.H., Loudon P., and Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40 (2006) 86-97
17. Yang N.S., Burkholder J., Roberts B., Martinell B., and McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 87 (1990) 9568-9572
18. Larregina A.T., Watkins S.C., Erdos G., Spencer L.A., Storkus W.J., Beer Stolz D., et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 8 (2001) 608-617
19. Cassaday R.D., Sondel P.M., King D.M., Macklin M.D., Gan J., Warner T.F., et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 13 (2007) 540-549
20. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91 (2004) 688-694
21. Tollefsen S., Tjelle T., Schneider J., Harboe M., Wiker H., Hewinson G., et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 20 (2002) 3370-3378
22. Powell K. DNA vaccines-back in the saddle again?. Nat Biotechnol 22 (2004) 799-801
23. Harrop R., John J., and Carroll M.W. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 58 (2006) 931-947
24. Liu M., Acres B., Balloul J.M., Bizouarne N., Paul S., Slos P., et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14567-14571
25. Timm A., Enzinger C., Felder E., and Chaplin P. Genetic stability of recombinant MVA-BN. Vaccine 24 (2006) 4618-4621
26. Havenga M., Vogels R., Zuijdgeest D., Radosevic K., Mueller S., Sieuwerts M., et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER. C6 cells. J Gen Virol 87 (2006) 2135-2143
27. Kamen A., and Henry O. Development and optimization of an adenovirus production process. J Gene Med 6 Suppl 1 (2004) S184-S192
28. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16 (2005) 1016-1027
29. Zhu J., Martinez J., Huang X., and Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109 (2007) 619-625
30. Thompson L.J., Kolumam G.A., Thomas S., and Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 177 (2006) 1746-1754
31. Gulley J., Chen A.P., Dahut W., Arlen P.M., Bastian A., Steinberg S.M., et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53 (2002) 109-117
32. Tartaglia J., Cox W.I., Pincus S., and Paoletti E. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand 82 (1994) 125-129
33. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 (1992) 217-232
34. Sutter G., and Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 84 (1995) 195-200
35. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339 (1992) 1429-1432
36. Paoletti E., Taylor J., Meignier B., Meric C., and Tartaglia J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev Biol Stand 84 (1995) 159-163
37. Velu T., Ramlau E., Quoix M., Pawlicki M., Pless H., Lena E., et al. A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL-2) in association with chmotherapy in patients with Non Small Cell Lung Cancer. J Clin Oncol 23 (2005) [No. 16S Part I of II: 7132]
38. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
39. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
40. Dreicer R., Ahman R., Pantuck A., Stadler W.M., Bizouarne N., Acres B., et al. Vaccine immunotherapy with MVA-Muc1-IL-2 (TG4010) in prostate cancer patients with biochemical failure. J Clin Oncol 23 (2005) [No. 16S Part I of II]
41. Dietrich P.Y., Kaufman R.H., Goff B., Mathioudakis G., Baudin M., Balloul J.M., et al. Immunogenicity of a non-replicative Vaccinia virus expressing the E6 and E7 early genes of HPV16 in patients with cervical neoplasia. Eur Soc Gene Ther (2003)
42. Mathevet P., Bory J.P., Huynh B., Bonnier P., Lécuru F., Riethmuller D., et al. Phase II study of MVA expressing E6 and E7 of HPV16 in patients with CIN2/3. 7th Annual Meeting, American Society of Gene Therapy (2004)
43. Brun J.L., Bory J.P., Levêque J., Mathevet P., Raulic P., Baldauf J.J., et al. Twelve-month follow-up data of the HPV16 CIN2/3 women having responded to Transgene's therapeutic vaccine TG4001. 23rd International Papillomavirus Conference (2006)
44. Garcia-Hernandez E., Gonzalez-Sanchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzman C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13 (2006) 592-597
45. Southall P.J., Boxer G.M., Bagshawe K.D., Hole N., Bromley M., and Stern P.L. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61 (1990) 89-95
46. Harrop R., Connolly N., Redchenko I., Valle J., Saunders M., Ryan M.G., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12 (2006) 3416-3424
47. Harrop R., Hawkins R., Anthiney A., Steven N., Habib N., Griffiths R., et al. Open label phase II studies of modified vaccinia ankara expressing the tumour antigen 5T4 given in conjunction with IFL and FOLFOX chemotherapy regimens: final analysis of safety and immunogenicity of MVA 5T4 given before, during and after chemotherapy. J Clin Oncol 24 18S (2006)
48. Griffiths R.W., Gilham D.E., Dangoor A., Ramani V., Clarke N.W., Stern P.L., et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 93 (2005) 670-677
49. Drexler I., Antunes E., Schmitz M., Wolfel T., Huber C., Erfle V., et al. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 59 (1999) 4955-4963
50. Meyer R.G., Britten C.M., Siepmann U., Petzold B., Sagban T.A., Lehr H.A., et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 54 (2005) 453-467
51. Lindsey K.R., Gritz L., Sherry R., Abati A., Fetsch P.A., Goldfeder L.C., et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 12 (2006) 2526-2537
52. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 93 (1996) 11349-11353
53. Menon A.G., Kuppen P.J., van der Burg S.H., Offringa R., Bonnet M.C., Harinck B.I., et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 10 (2003) 509-517
54. Ullenhag G.J., Frodin J.E., Mosolits S., Kiaii S., Hassan M., Bonnet M.C., et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 9 (2003) 2447-2456
55. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23 (2005) 9008-9021
56. Spaner D.E., Astsaturov I., Vogel T., Petrella T., Elias I., Burdett-Radoux S., et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 106 (2006) 890-899
57. Karanikas V., Lurquin C., Colau D., van Baren N., De Smet C., Lethe B., et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171 (2003) 4898-4904
58. Nemunaitis J., Meyers T., Senzer N., Cunningham C., West H., Vallieres E., et al. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 13 (2006) 1185-1191
59. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 (2003) 8729-8735
60. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
61. Emini E.A. Status of the Merc HIV-1 vaccine program. Keystone Symposia on HIV-1Vaccine Development (2003)
62. Holterman L., Vogels R., van der Vlugt R., Sieuwerts M., Grimbergen J., Kaspers J., et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78 (2004) 13207-13215
63. Chillon M., Lee J.H., Fasbender A., and Welsh M.J. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 5 (1998) 995-1002
64. Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., ElBash M., Lanuti M., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 9 (1998) 2121-2133
65. Croyle M.A., Chirmule N., Zhang Y., and Wilson J.M. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75 (2001) 4792-4801
66. Seshidhar Reddy P., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311 (2003) 384-393
67. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346 (2006) 394-401
68. Weber J., Sondak V.K., Scotland R., Phillip R., Wang F., Rubio V., et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97 (2003) 186-200
69. Harrington L.E., Most Rv R., Whitton J.L., and Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76 (2002) 3329-3337
70. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74 (2000) 7651-7655
71. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 (2003) 21-29
72. Mackova J., Stasikova J., Kutinova L., Masin J., Hainz P., Simsova M., et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 55 (2006) 39-46
73. Pasquini S., Peralta S., Missiaglia E., Carta L., and Lemoine N.R. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther 9 (2002) 503-510
74. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 (2002) 4391-4398
75. Vordermeier H.M., Rhodes S.G., Dean G., Goonetilleke N., Huygen K., Hill A.V., et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112 (2004) 461-470
76. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20 (2002) 1949-1955
77. Michelini Z., Negri D.R., Baroncelli S., Catone S., Comini A., Maggiorella M.T., et al. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge. J Med Primatol 33 (2004) 251-261
78. Nilsson C., Makitalo B., Berglund P., Bex F., Liljestrom P., Sutter G., et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19 (2001) 3526-3536
79. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 (2004) 3930-3940
80. Schneider J., Langermans J.A., Gilbert S.C., Blanchard T.J., Twigg S., Naitza S., et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19 (2001) 4595-4602
81. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 (2003) 729-735
82. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
83. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80 (2006) 4717-4728
84. Schneider J., Gilbert S.C., Hannan C.M., Degano P., Prieur E., Sheu E.G., et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 170 (1999) 29-38
85. Estcourt M.J., Ramsay A.J., Brooks A., Thomson S.A., Medveckzy C.J., and Ramshaw I.A. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 14 (2002) 31-37
86. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73 (1999) 7524-7532
87. Degano P., Schneider J., Hannan C.M., Gilbert S.C., and Hill A.V. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18 (1999) 623-632
88. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 (1998) 397-402
89. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., and Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 (2000) 605-609
90. Smith C.L., Dunbar P.R., Mirza F., Palmowski M.J., Shepherd D., Gilbert S.C., et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113 (2005) 259-266
91. Thomson S.A., Elliott S.L., Sherritt M.A., Sproat K.W., Coupar B.E., Scalzo A.A., et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 157 (1996) 822-826
92. Toes R.E., Hoeben R.C., van der Voort E.I., Ressing M.E., van der Eb A.J., Melief C.J., et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 94 (1997) 14660-14665
93. Oertli D., Marti W.R., Zajac P., Noppen C., Kocher T., Padovan E., et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 13 (2002) 569-575
94. Hawkins R.E., Dangoor A., Keilholz U., Schadendorf D., Harris A., Ottensmeier C.H., et al. Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. J Clin Oncol 24 18S (2006) 8030
95. Garnett C.T., Greiner J.W., Tsang K.Y., Kudo-Saito C., Grosenbach D.W., Chakraborty M., et al. TRICOM vector based cancer vaccines. Curr Pharm Des 12 (2006) 351-361
96. Petrulio C.A., and Kaufman H.L. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 5 (2006) 9-19
97. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 23 (2005) 662-664
98. Luo Y., O'Hagan D., Zhou H., Singh M., Ulmer J., Reisfeld R.A., et al. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 21 (2003) 1938-1947
99. Mollenkopf H.J., Dietrich G., Fensterle J., Grode L., Diehl K.D., Knapp B., et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22 (2004) 2690-2695
100. O'Hagan D.T., Singh M., and Ulmer J.B. Microparticle-based technologies for vaccines. Methods 40 (2006) 10-19
101. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22 (2004) 2489-2493
102. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8 (2002) 1028-1037
103. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 (2007) 5257-5269
104. Tollefsen S., Vordermeier M., Olsen I., Storset A.K., Reitan L.J., Clifford D., et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol 57 (2003) 229-238
105. Liu M.A., Wahren B., and Karlsson Hedestam G.B. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 17 (2006) 1051-1061
106. Arrington J., Braun R.P., Dong L., Fuller D.H., Macklin M.D., Umlauf S.W., et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 76 (2002) 4536-4546
107. Warren T.L., and Weiner G.J. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 7 (2000) 168-173
108. Greenland J.R., and Letvin N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25 (2007) 3731-3741
109. Stevenson F.K., Ottensmeier C.H., Johnson P., Zhu D., Buchan S.L., McCann K.J., et al. DNA vaccines to attack cancer. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14646-14652
110. Polo J.M., Gardner J.P., Ji Y., Belli B.A., Driver D.A., Sherrill S., et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel) 104 (2000) 181-185